Tags

Type your tag names separated by a space and hit enter

Biologic Therapies for Immunoglobulin E-mediated Food Allergy and Eosinophilic Esophagitis.
Immunol Allergy Clin North Am 2017; 37(2):369-396IA

Abstract

Immunoglobulin (Ig) E-mediated food allergy and eosinophilic esophagitis (EoE) are chronic, allergen-mediated disorders characterized by an aberrant TH2 immune response. The development and investigation of biologics for the treatment of IgE-mediated food allergy and eosinophilic esophagitis have provided further insight into the pathophysiology and management of these disorders. This article provides an overview of biologic therapies that are being investigated or have potential as treatments for IgE-mediated food allergy and eosinophilic esophagitis. Identification of EoE phenotypes that are responsive to biologics and investigation of biologics combined with other therapies may help elucidate a role for biologics in EoE.

Authors+Show Affiliations

Department of Medicine, Sean N. Parker Center for Allergy and Asthma Research, Stanford University, Palo Alto, CA, USA. Electronic address: kagome@stanford.edu.Department of Medicine, Sean N. Parker Center for Allergy and Asthma Research, Stanford University, Palo Alto, CA, USA.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

28366483

Citation

Otani, Iris M., and Kari C. Nadeau. "Biologic Therapies for Immunoglobulin E-mediated Food Allergy and Eosinophilic Esophagitis." Immunology and Allergy Clinics of North America, vol. 37, no. 2, 2017, pp. 369-396.
Otani IM, Nadeau KC. Biologic Therapies for Immunoglobulin E-mediated Food Allergy and Eosinophilic Esophagitis. Immunol Allergy Clin North Am. 2017;37(2):369-396.
Otani, I. M., & Nadeau, K. C. (2017). Biologic Therapies for Immunoglobulin E-mediated Food Allergy and Eosinophilic Esophagitis. Immunology and Allergy Clinics of North America, 37(2), pp. 369-396. doi:10.1016/j.iac.2017.01.010.
Otani IM, Nadeau KC. Biologic Therapies for Immunoglobulin E-mediated Food Allergy and Eosinophilic Esophagitis. Immunol Allergy Clin North Am. 2017;37(2):369-396. PubMed PMID: 28366483.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Biologic Therapies for Immunoglobulin E-mediated Food Allergy and Eosinophilic Esophagitis. AU - Otani,Iris M, AU - Nadeau,Kari C, PY - 2017/4/4/entrez PY - 2017/4/4/pubmed PY - 2017/12/23/medline KW - Anti-IgE KW - Anti–IL-13 KW - Anti–IL-5 KW - Eosinophilic esophagitis KW - Food allergy KW - OC000459 KW - QAX576 SP - 369 EP - 396 JF - Immunology and allergy clinics of North America JO - Immunol Allergy Clin North Am VL - 37 IS - 2 N2 - Immunoglobulin (Ig) E-mediated food allergy and eosinophilic esophagitis (EoE) are chronic, allergen-mediated disorders characterized by an aberrant TH2 immune response. The development and investigation of biologics for the treatment of IgE-mediated food allergy and eosinophilic esophagitis have provided further insight into the pathophysiology and management of these disorders. This article provides an overview of biologic therapies that are being investigated or have potential as treatments for IgE-mediated food allergy and eosinophilic esophagitis. Identification of EoE phenotypes that are responsive to biologics and investigation of biologics combined with other therapies may help elucidate a role for biologics in EoE. SN - 1557-8607 UR - https://www.unboundmedicine.com/medline/citation/28366483/Biologic_Therapies_for_Immunoglobulin_E_mediated_Food_Allergy_and_Eosinophilic_Esophagitis_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0889-8561(17)30010-3 DB - PRIME DP - Unbound Medicine ER -